Managing trastuzumab deruxtecan-related adverse events in patients with metastatic breast cancer: insights from a worldwide survey of the Hermione EDUcational project

Trastuzumab deruxtecan (T-DXd) has shown remarkable efficacy in phase III trials in patients with HER2-positive early- and late-stage breast cancer and HER2-low/ultra-low metastatic breast cancer (mBC). However, toxicities remain prevalent and clinically relevant, leading to dose reductions/interruptions or discontinuation. A survey was conducted across oncologists in 13 countries worldwide to collect experiences in managing T-DXd-related toxicities, focusing on nausea/vomiting, fatigue, and interstitial lung disease (ILD) as key areas of clinical concern. Ninety-nine experts participated in the survey. Nausea and fatigue were the most common toxicities, reported by 91.9% and 94.9% of respondents, respectively. 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids were “very often” prescribed for prophylaxis. The frequency of use of second‑generation 5‑HT3 receptor antagonists varied among respondents. Most frequently, they employed an NK1 receptor antagonist combined with corticosteroids and 5‑HT3 receptor antagonists. Forty-four percent of respondents prescribed 4‑drug regimens incorporating NK1 receptor antagonists and olanzapine to all patients with nausea/vomiting above grade 1 in the first cycle, 35% reserved them for high‑risk patients, and 21% used them for all patients from cycle one. For all respondents, patients receiving T‑DXd experienced fatigue, with 65% observing it in more than 60% of patients, and most considered nausea/vomiting and fatigue to moderately or significantly affect daily activities and quality of life. ILD was reported as rare or occasional and was generally monitored using computed tomography. Real-life management of T-DXd-related toxicities is complex and needs an ongoing comprehensive evaluation of patients before, during and after therapy, with a highly trained/skilled multidisciplinary team.

Authors

Institutions

Publication Details

Journal
Supportive Care in Cancer
Published
2026-10-31
DOI
https://doi.org/10.1007/s00520-026-11393-4
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Managing trastuzumab deruxtecan-related adverse events in patients with metastatic breast cancer: insights from a worldwide survey of the Hermione EDUcational project

Fei Ma, Matti Aapro, Hennessy Bryan, Maria Lapuente et al.
Supportive Care in Cancer
HER2/EGFR in Cancer Research
article

Managing trastuzumab deruxtecan-related adverse events in patients with metastatic breast cancer: insights from a worldwide survey of the Hermione EDUcational project

Fei Ma, Matti Aapro, Hennessy Bryan, Maria Lapuente, Marina Elena Cazzaniga, Hirotoshi Iihara, Benjamín Walbaum, Andreas Charalambous, Laura Cortesi, Kelly Elizabeth McCann, Gilles Freyer, Hope S. Rugo, Yeon Hee Park, Florian Strasser, Luis Costa, Hitomi Sakai, Manuel Alva Bianchi, Ana Belén Rodríguez García, Peter Fashing, Shusen Wang, Irati Rodriguez Matesanz
article en

Abstract

Trastuzumab deruxtecan (T-DXd) has shown remarkable efficacy in phase III trials in patients with HER2-positive early- and late-stage breast cancer and HER2-low/ultra-low metastatic breast cancer (mBC). However, toxicities remain prevalent and clinically relevant, leading to dose reductions/interruptions or discontinuation. A survey was conducted across oncologists in 13 countries worldwide to collect experiences in managing T-DXd-related toxicities, focusing on nausea/vomiting, fatigue, and interstitial lung disease (ILD) as key areas of clinical concern. Ninety-nine experts participated in the survey. Nausea and fatigue were the most common toxicities, reported by 91.9% and 94.9% of respondents, respectively. 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids were “very often” prescribed for prophylaxis. The frequency of use of second‑generation 5‑HT3 receptor antagonists varied among respondents. Most frequently, they employed an NK1 receptor antagonist combined with corticosteroids and 5‑HT3 receptor antagonists. Forty-four percent of respondents prescribed 4‑drug regimens incorporating NK1 receptor antagonists and olanzapine to all patients with nausea/vomiting above grade 1 in the first cycle, 35% reserved them for high‑risk patients, and 21% used them for all patients from cycle one. For all respondents, patients receiving T‑DXd experienced fatigue, with 65% observing it in more than 60% of patients, and most considered nausea/vomiting and fatigue to moderately or significantly affect daily activities and quality of life. ILD was reported as rare or occasional and was generally monitored using computed tomography. Real-life management of T-DXd-related toxicities is complex and needs an ongoing comprehensive evaluation of patients before, during and after therapy, with a highly trained/skilled multidisciplinary team.

Supportive Care in CancerVol. 34(11)
University of Bern (CH), SHOWA Medical University (JP), University of Modena and Reggio Emilia (IT), City Of Hope National Medical Center (US), St Bartholomew's Hospital (GB), University of Lisbon (PT), Royal College of Surgeons in Ireland (IE), Sun Yat-sen University (CN), Pontificia Universidad Católica de Chile (CL), Cyprus University of Technology (CY), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Université de Lyon (FR), Samsung Medical Center (KR), University of California San Diego (US), Research Institute Hospital 12 de Octubre (ES), Universitätsklinikum Erlangen (DE), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Hospices Civils de Lyon (FR), Hospital Universitario 12 De Octubre (ES), Gifu University Hospital (JP), Clinique de Genolier (CH), City of Hope (US), Hospital Clínic de Barcelona (ES), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Comprehensive Cancer Center Erlangen (DE), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Gulbenkian Institute for Molecular Medicine (PT), Unidade Local de Saúde Santa Maria (PT), University of Milano-Bicocca (IT), Universitat de Barcelona (ES), Sungkyunkwan University (KR)
Openalex Percentile: Top 15%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon